Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application

If approved, the investigational therapy would offer a new treatment option for patients with advanced gastric and gastroesophageal cancers TOKYO, July 6, 2023 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food…